Upstate Active Clinical Trials

Study Title:

VX20-121-103: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation

Upstate Institutional Review Board (IRB) Number:

1797977

Study/Protocol ID:

VX20-121-103

Patient Age Group:

Adults and Children

Principal Investigator:

Christopher N Fortner, MD

ClinicalTrials.Gov ID:

NCT05076149

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Mary Forell
Phone: 315-464-9209
Email: [email protected]

Return to Previous Page || Search Again